US Stock MarketDetailed Quotes

BNTX BioNTech

Watchlist
  • 120.690
  • +1.350+1.13%
Close Dec 12 16:00 ET
  • 120.690
  • 0.0000.00%
Post 16:15 ET
28.93BMarket Cap-59.28P/E (TTM)

About BioNTech Company

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Company Profile

SymbolBNTX
Company NameBioNTech
Listing DateOct 10, 2019
Issue Price15.00
Founded2008
CEOProfessor Ugur Sahin, M.D.
MarketNASDAQ
Employees6133
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressAn der Goldgrube 12
CityMainz
ProvinceRheinland-Pfalz
CountryGermany
Zip Code55131
Phone49-6131-9084-0
Websitehttp://www.biontech.de

Company Executives

  • Name
  • Position
  • Salary
  • Professor Ugur Sahin, M.D.
  • Chief Executive Officer
  • 3.06M
  • Jens Holstein
  • Chief Financial Officer
  • 1.32M
  • Dr. Sierk Poetting, PhD
  • Chief Operating Officer
  • 821.00K
  • Dr. Ozlem Tureci, M.D.
  • Chief Medical Officer
  • 814.00K
  • Ryan Richardson
  • Chief Strategy Officer
  • 1.41M
  • James Ryan, PhD
  • Chief Legal Officer
  • --
  • Helmut Jeggle
  • Chairman of the Supervisory Board
  • 226.00K
  • Dr. Ulrich Wandschneider, PhD
  • Deputy Chairman of the Supervisory Board
  • 114.00K
  • Michael Motschmann
  • Member of the Supervisory Board
  • 80.00K
  • Professor Rudolf Staudigl, PhD
  • Member of the Supervisory Board
  • 90.00K
  • Professor Anja Morawietz, PhD
  • Member of the Supervisory Board
  • 105.00K
  • Baroness Nicola Blackwood
  • Member of the Supervisory Board
  • 46.00K
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday-0.55%